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Abstract Introduction
T cells respond to peptide antigen in association with MHC
products on antigen-presenting cells (APCs). A number of ac-
cessory or costimulatory molecules have been identified that
also contribute to T cell activation. Several of the known acces-
sory molecules are expressed by freshly isolated dendritic cells,
a distinctive leukocyte that is the most potent APC for the
initiation of primary T cell responses. These include ICAM-1
(CD54), LFA-3 (CD58), and class I and II MHCproducts.
Dendritic cells also constitutively express the accessory ligand
for CD28, B7/BB1, which has not been previously identified on
circulating leukocytes freshly isolated from peripheral blood.
Dendritic cell expression of both B7/BB1 and ICAM-1 (CD54)
increases after binding to allogeneic T cells. Individual mAbs
against several of the respective accessory T cell receptors, e.g.,
anti-CD2, anti-CD4, anti-CD1 la, and anti-CD28, inhibit T cell
proliferation in the dendritic cell-stimulated allogeneic mixed
leukocyte reaction (MLR) by 40-70%. Combinations of these
mAbsare synergistic in achieving near total inhibition. Other T
cell-reactive mAbs, e.g., anti-CD5 and anti-CD45, are not inhib-
itory. Lymphokine secretion and blast transformation are simi-
larly reduced when active accessory ligand-receptor interac-
tions are blocked in the dendritic cell-stimulated allogeneic
MLR. Dendritic cells are unusual in their comparably higher
expression of accessory ligands, among which B7/BB1 can now
be included. These are pertinent to the efficiency with which
dendritic cells in small numbers elicit strong primary T cell
proliferative and effector responses. (J. Clin. Invest. 1992.
90:229-237.) Key words: dendritic cells * B7/BB1 * CD28, T
cell activation * antigen-presenting cells * costimulation
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Antigen-presenting cells (APCs)' express cell surface molecules
that are known to enhance T cell responses to peptide-MHC
complexes (1-3). These costimulatory or accessory molecules
pair with specific receptors on the T cell. Several of these molec-
ular couples have been characterized: LFA-3 (CD58) with CD2
(4, 5), ICAM- 1 (CD54) with LFA- 1 (CD I I a) (6), B7/BB 1 with
CD28 (7-10) and/or CTLA-4 (11), CD72 with CD5 (12), and
class I or II MHCwith CD8 (13) or CD4 (14), respectively.
However, these accessory ligands have not always been identi-
fied on circulating leukocytes, and their roles have usually been
evaluated using expanded T cell clones already activated by
antigen and heterogeneous feeder cells.
Prior work has established that dendritic cells, which repre-
sent a trace but distinctive leukocyte subset, are the most po-
tent APC for the induction of primary, antigen-specific T cell
responses in vitro and in situ (15). Amongthe known accessory
couples, the interaction between B7/BB 1 and CD28 is the only
one that appears to stimulate T cell proliferation by a direct
effect on IL-2 production (16-19). Wetherefore investigated
whether dendritic cells expressed the accessory molecule B7/
BB1, in addition to their known high expression of ICAM-1
(CD54), LFA-3 (CD58), and MHCclass I and II products (20-
22). Wereport that all are expressed by dendritic cells and that
B7/BB1 and ICAM-1 (CD54) specifically increase after den-
dritic cell binding to primary CD4+lymphocytes. Using mAbs
directed against the T cell receptors for these costimulatory
molecules, we also demonstrate the functional roles of these
accessory couples in the complete activation of primary T cells
in the allogeneic mixed leukocyte reaction (MLR).
Methods
Culture medium, serum, and buffers
Cells were cultured in RPMI 1640 (Gibco Laboratories, Grand Island,
NY) supplemented with 10 mMHepes (Sigma Chemical Co., St.
Louis, MO), 1 mMglutamine (JRH Biosciences, Lenexa, KS), 5 x I0-'
M2-mercaptoethanol (Eastman Kodak Co., Rochester, NY), penicil-
lin (100 U/ml)-streptomycin (100 gg/ml) (JRH Biosciences), and 5 or
10% serum. FCS (JRH Biosciences) was used for short term culture of
T cells, before stimulation in MLRs. Normal human serum (NHS),
obtained from fasting, healthy, untransfused male donors was used to
culture all non-T cell fractions and allogeneic MLRs. Only Ca2+- and
1. Abbreviations used in this paper: APCs, antigen-presenting cells; B-
LCL, B-lymphoblastoid cell lines; ER-, erythrocyte-negative; Er',
erythrocyte-positive; MLR, mixed leukocyte reaction.
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Mg2e-free saline buffers ([PBS or HBSS] or bovine calf serum [BCS];
JRH Biosciences) 5% vol/vol in RPMI were used for cell washes. All
sera were heat-inactivated at 560C for 30 min to deplete complement.
All cell cultures were maintained at 370C in humidified 7%Co2.
Monoclonal antibodies
mAbs used in the functional in vitro assays and for the isolation of T
lymphocyte subsets were: anti-HLA class II, DR-specific (L243, IgG2a;
Xth International Histocompatibility Workshop), and monomorphic
DR/DQ-specific (9.3F10, IgG2a, HB180; American Type Culture Col-
lection [ATCC], Rockville, MD); anti-CD2, recognizing the LFA-3
(CD58) binding site (TS2/18, IgGl, HB 195; ATCC); anti-CD4 (Leu3a/
IgG I; gift of Dr. Robert Evans, NewYork); anti-CD5 (6-2, IgG2a; B.
Dupont); anti-CD8 (OKT8, IgG2a, CRL 8014; ATCC; SA 19-11,
IgGl; gift of Dr. S. Y. Yang, NewYork); anti-CDl la (TS1/22, IgGl,
HB202; ATCC); anti-CD14 (3C10, IgG2b, TIB 228; ATCC; LeuM3,
IgGl; Becton-Dickinson Microbiology Sys., Mountain View, CA);
anti-CD16 (Leul lb, IgM; Becton-Dickinson Microbiology Sys.); anti-
CD18 (IB4, IgG2a; gift of Dr. S. D. Wright, NewYork [23]); anti-CD25
(anti-TAC, IgG2a; gift of Dr. T. Waldmann, Bethesda, MD; 6G,
IgG2a, gift of Dr. S. Y. Yang, NewYork); anti-CD28 (9.3, IgG2a; gift of
Dr. Jeffrey Ledbetter, Seattle, WA); anti-CD45 (4B2, IgG2a, HB 196;
ATCC); anti-CD45RA (4G 10, IgG2a; R. M. Steinman); anti-CD45RO
(UCHL-1, IgG2a; gift of Dr. P. C. L. Beverley, London, UK[24, 25]);
anti-CD54 (LB2, IgG2a, FITC-conjugated; E. A. Clark); anti-CD56
(Leu19, IgGl; Becton-Dickinson Microbiology Sys.); anti-CD57
(Leu7, IgM; Becton Dickinson Microbiology Sys.); anti-CD58 (LFA-3,
IgGl, HB 205; ATCC); anti-BBl (anti-B cell activation antigen B7/
BB1, IgM, both unconjugated and FITC-conjugated; E. A. Clark [26]).
All murine anti-human mAbs used in the functional in vitro assays
were purified as whole immunoglobulin from murine ascites or serum-
free hybridoma supernatants and quantified at OD280. F(ab')2 frag-
ments were not used in the functional assays, as blood dendritic cells do
not have detectable FcR (27). For isolation of lymphocyte subsets, ei-
ther murine ascites or hybridoma supernatants were applied at previ-
ously determined effective concentrations. Cytofluorographic analyses
of T lymphocyte subset purity and accessory ligand expression were
performed on a FACScan" instrument (Becton-Dickinson Immunocy-
tometry Systems, Mountain View, CA). Commercial mAbs for stain-
ing were purchased already conjugated to either FITC or PE; otherwise,
FITC-conjugated F(ab')2 goat anti-mouse IgG + IgM (4353; TAGO,
Inc., Burlingame, CA) was used as a second-step reagent for indirect
staining. WeFITC-conjugated anti-BB I and LB2 (CD54) according to
standard methods (28). Stained cells were analyzed by cytofluorogra-
phy on a FACScan® instrument (Becton-Dickinson Immunocytome-
try Systems). Commercial murine IgGl/MOPC21 and IgM/TEPC 183
(Sigma Chemical Co.) were used as isotype-matched controls if compa-
rable T cell-reactive mAbs were not available.
Because a human blood dendritic cell-specific mAbwas not avail-
able, dendritic cells were analyzed cytofluorographically by gating cells
with large forward scatter that did not stain with a panel of PE-conju-
gated cell-specific mAbs to B and T lymphocytes, monocytes/macro-
phages, and NKcells ([20]; see also Results, Fig. 1). Having excluded
nondendritic cell PBMCfrom the analysis gate, dendritic cells were
then analyzed for positive counterstaining by a FITC-conjugated mAb
to the epitope of interest.
PBMCand preparation of leukocyte subpopulations
PBMCand the mononuclear subpopulations of interest were prepared
according to previously published procedures (20, 27, 29). In sum-
mary, hepatitis and HIV-seronegative PBMCwere obtained from
freshly drawn normal leukocyte concentrates (Greater NYBlood Pro-
gram, NewYork) by centrifugation over Ficoll-Paque (Pharmacia Fine
Chemicals, Piscataway, NJ) at 1,000 g for 20 min at room temperature.
PBMCwere washed in PBS and rosetted with neuraminidase-treated
(Vibrio cholerae neuraminidase; Calbiochem-Behring Corp., LaJolla,
CA) sheep erythrocytes (Cocalico Biologicals, Inc., Reamstown, PA).
These were separated over Ficoll-Paque into erythrocyte-negatiye (Er-)
and erythrocyte-positive (Er') fractions.
Purification of T lymphocytes and their subsets. Er' lymphocytes
were passed over nylon wool columns (18369; Polysciences, Inc.,
Warrington, PA), and CD4' T lymphocytes were purified by negative
selection from the Er', nylon wool nonadherent fraction. Cells opson-
ized by mAbs against CD8, CD14, CD16, CD25, CD56, CD57, and
MHCclass II loci were eliminated by (a) two rosettings with goat-anti-
mouse Ig-coated magnetic beads [Dynabeads M-450; DYNALInc.,
Great Neck, NY), followed by Ab/C (rabbit complement; Gibco Labo-
ratories)-mediated lysis (30); or (b) two to three pannings over goat-
anti-mouse IgG-coated (55459, anti-IgG Fc 7y-chain specific; Cappel,
Organon Teknika, Durham, NC) petri dishes (31, 32). Cytofluorog-
raphy confirmed a resulting population of > 98%CD3+/CD4' T cells,
contaminated by < 1%HLA-DR', CD25', CD16+ cells. For some pre-
liminary experiments we also separated the CD4+ lymphocytes into
CD4+/CD45RA- and CD4+/CD45RO- subsets by similar negative se-
lection (30).
Enrichment ofdendritic cells (20, 27, 29). After the Er- fraction had
been cultured - 36 h in RPMI 10% NHS, the nonadherent cells were
collected and panned twice over human Ig-coated (10 mg/ml; Cappel,
Organon Teknika) petri dishes to deplete contaminant monocytes,
which adhered via their Fc receptors (27). A final adherence step to
tissue culture plastic was performed at 37°C for 30-45 min. This
Er-FcR- plastic nonadherent population was resuspended, overlaid on
3 ml of 14.5 g%metrizamide [20, 29]; Metrizamide AG, 222010; Ny-
comed AS, Oslo, Norway), and centrifuged at 650 gfor 10 min at room
temperature. The resulting interface was collected and washed twice in
decreasingly hypertonic medium (11.34 and 10.43 g%NaCl in RPMI
5%FCS, equivalent to 40 mMand 25 mMNaCl, respectively) before a
final wash in isotonic medium (20). This interface contained blood
dendritic cells at - 40-60% purity, easily identified by phase micros-
copy on a hemacytometer, the major contaminants being B lympho-
cytes by cytofluorographic analysis. The purity of the DCpopulation
could be improved to 80-90% by panning depletion of residual
CD45RA+(4G 10) B lymphocytes and CD14+(3C 10) monocytes (20).
The high density pellet from the metrizamide gradient consisted almost
entirely of B lymphocytes and was discarded.
Allogeneic MLR
T cells and dendritic cells were combined from random allogeneic leu-
kocyte concentrates. Enriched dendritic cells were y-irradiated (3,000
rad 137Cs) and added to T lymphocytes at the APC:T ratios indicated
in the respective experiments, typically 1:25 or 1:30. MLRswere cul-
tured in RPMI 10% NHS, either in 16 mm, 24-well flat-bottomed (1.5
X 106 T cells/well; Costar Corp., Cambridge, MA) or 96-microwell
flat-bottomed (1.5 X 105 T cells/well; Coming Glass, Inc., Coming,
NY) tissue culture plates.
Inhibitory effects of various mAbs were assayed in the allogeneic
MLR. T cells (or APCs in the case of anti-BB I and anti-class II MHC)
were incubated directly with the mAb(s) of interest in flat-bottomed
microwells for 30-60 min at 4°C with gentle shaking. The cells were
not washed before addition of the opposite MLRparty. The cells were
then placed at 37°C for the duration of culture. In certain experiments
in which mAbswere added at different time points during culture, the
plate was placed at 4°C for 30-60 min after addition of the mAbsand
then returned to 37°C.
MLRproliferative activity was measured by the incorporation of
[3H]thymidine (1 MCi/microwell, NewEngland Nuclear, Boston, MA)
over 8-12 h typically on d4 -* 5. Cells were harvested on glass fiber
filters and counted (1205 Betaplate; Pharmacia LKB Biotechnology,
Inc., Gaithersburg, MD). Responses have been reported as the mean
counts per minute±standard deviation of triplicates, and percent inhi-
bition by mAbs has been calculated with regard to isotype-matched
controls.
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Assay of T cell growth factor in the MLR
Aliquots of MLRsupernatants were harvested at 40-48 h and frozen
until assayed. The growth of a CTLL2 line in the presence of MLR
supernatants was compared with that of a standard curve using graded
doses of rhIL-2 ([33]; Cetus Corp., Emeryville, CA). The amount of T
cell growth factor in the MLRsupernatants was then expressed in terms
of IU rhIL-2/ml (1 Cetus Unit = 6 IU rhIL-2).
Assay of blast transformation in the MLR
Cohort wells of allogeneic MLRsbeing assayed for proliferation were
stained with 0.5% vol/vol propidium iodide (P4170; Sigma Chem. Co.)
and monitored by cytofluorography (FACScan; Becton-Dickinson Im-
munocytometry Systems). Propidium iodide-(FL2) positive cells were
nonviable and excluded from analysis. Propidium iodide-negative cells
were gated on the basis of forward light scatter in order to calculate the
percentage of blasts.
Separation of alloreactive T cell-dendritic cell aggregates or
clusters
Previous studies have shown that dendritic cells and responding T cells
in the MLRcluster together to form discrete aggregates (31, 34, 35).
After 40 h of MLRculture, half the supernatant from each MLRin a
16-mm macrowell was removed and replaced with serum-free RPMI,
resulting in 5% vol/vol NHS/RPMI. The cells were gently harvested,
overlayed on 5 ml of 30%vol/vol FCS/RPMI, and placed on ice. Allore-
active T cells, which had clustered with allogeneic dendritic cells in the
MLR, settled by gravity over - 45 min. Nonreactive T cells in the
responder population that had not formed clusters remained at or near
the interface. Clusters were collected from the lowest 2 ml, washed in
Ca2" and Mg2" -free PBS, vigorously resuspended, and counted. Clus-
ters were either analyzed by cytofluorography, as an enriched source of
dendritic cells that had bound alloreactive T cells, or they were recul-
tured at 2.5-5 X 104 cells/100 Al in triplicate round-bottomed micro-
wells for assessment of proliferation.
MLRclusters could be sufficiently disrupted at 40 h to release ade-
quate numbers of individual dendritic cells for cytofluorographic analy-
sis. However, the reverse was not true for clustered T cells, some of
which remained tightly bound to dendritic cells that invariably contam-
inated the T cell gate on cytofluorography. Therefore, separate analyses
of lymphoblasts were undertaken using highly purified (2 99%)
CD4+CD3+, APC-free lymphocytes stimulated for 2 d with concanava-
lin A ([Con A] 4 jig/ml), and PMA(5 ng/ml).
Results
Humanblood dendritic cells express accessory ligands and in-
crease their expression of B7/BBJ and ICAM-J (CD54) after
binding alloreactive T cells in the MLR. Enriched populations
of blood dendritic cells were analyzed by cytofluorography for
their expression of the accessory ligands B7/BB1, ICAM- 1
(CD54), LFA-3 (CD58), and class II MHCloci. Analyses were
conducted both before and after antigen-specific binding or
clustering with alloreactive CD4+T cells in the MLR. Primary
populations of circulating blood dendritic cells consistently ex-
pressed detectable levels of B7/BB1 (Fig. 1 J), although the
intensity of constitutive expression varied slightly between do-
nors. Freshly enriched blood dendritic cells also expressed high
amounts of ICAM- 1 (CD54) (Fig. 1 e), as well as LFA-3
(CD58) and MHCproducts, as previously reported (20, not
shown here). After Ag-specific binding with alloreactive CD4+
T cells, however, dendritic cells upregulated their expression of
both ICAM- I (CD54) and B7/BB 1 (Fig. 1, e andJ. The incre-
ments in ICAM- 1 (CD54) and B7/BB I expression by clustered
dendritic cells were specific, as we found no change in the ex-
pression of the leukocyte common antigen, CD45 (Fig. 1 d).
LFA-3 (CD58) expression also did not change, and expression
of MHCclass II antigens DRand DQincreased variably (not
shown). These findings were not altered by y-irradiating ('37Cs,
3,000 rad) the dendritic cells, increasing dendritic cell purity to
80-90% by panning depletion of residual CD45RA' and
CD14' contaminants in the metrizamide interface, or cluster-
ing dendritic cells with bulk T cell responders in lieu of CD4' T
cells in the MLR(not shown). Weattempted to assess alter-
ations in accessory ligand expression by dendritic cells cultured
in the absence of allogeneic T cells after 'y-irradiation. Purified
y-irradiated dendritic cells recultured alone for 40 h exhibited
variable viability that unfortunately prevented reliable evalua-
tion. When the cells did remain viable, only slight increases
were noted in the expression of both B7/BB 1 and ICAM- 1
(CD54), but always less than after antigen-specific clustering
with T cells in the allogeneic MLR.
Although T cells should have been excluded by the cyto-
fluorographic gating of dendritic cells above, we evaluated
whether T lymphoblasts themselves could express B7/BB 1. We
compared APC-free, Con A/phorbol myristate acetate
(PMA)-stimulated T cells with unstimulated T cell controls for
ICAM- 1 (CD54) and B7/BB 1 expression. Weconfirmed acti-
vation by the expression of p55IL-2R (CD25; Fig. 1 g). These
CD25+ T lymphoblasts increased their expression of the widely
distributed ICAM- 1 (CD54) marker as expected (Fig. 1 h).
However, B7/BB 1 was not expressed significantly above back-
ground by either the unstimulated controls or the Con A/
PMA-elicited T lymphoblasts (Fig. 1 i). Wetherefore infer that
T lymphocytes do not contribute to the increased B7/BB 1
found on clustered dendritic cells in the allogeneic MLR.
The accessory ligands expressed by blood dendritic cells are
involved in stimulating primary T cell proliferative responses to
alloantigen. Wefirst studied the function of the CD28:B7/BB I
couple, as blood dendritic cells constitute a primary leukocyte
subpopulation expressing B7/BB 1. The function of CD28 and
B7/BB1 in allogeneic MLRshad previously only been assessed
using B lymphoblastoid cell line stimulators (36). Wetherefore
stimulated CD4+ responder T cells with allogeneic dendritic
cells in the presence of mAbs against B7/BB 1 and its receptor
CD28, singly and in combination. A representative experiment
is shown in Fig. 2. Compared with isotype-matched controls,
anti-CD28 consistently inhibited the primary allogeneic MLR
by 40-70% (representative of 10 experiments). Anti-BBl was
typically less inhibitory than anti-CD28 (26-37% inhibition,
cf. IgM control in this experiment). The combination of mAbs
against BB1 and CD28, however, did not significantly increase
the inhibition effected by either mAbalone, consistent with
involvement of the same ligand:receptor couple in the den-
dritic cell T cell system. In contrast, the combination of anti-
CD28 and anti-CD2 (TS2/18) was additive in its inhibitory
effects, confirming interactions between more than one acces-
sory ligand/receptor pair.
We then studied the function of other accessory ligands
expressed by circulating blood dendritic cells (Table I). Intact
mAbs against the T cell accessory molecules, CD2, CD4,
CDl la, and CD28, were used to monitor inhibition of den-
dritic cell ligand binding and resultant T cell proliferation. The
dose of mAb(s) was varied while the responder:stimulator ratio
was held constant (Table I A), or vice versa (Table I B). Only
bulk CD4' lymphocyte responses are illustrated, since prelimi-
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Figure 1. Cytofluorographic analysis of accessory ligand expression by human blood dendritic cells. Humanblood dendritic cells were gated for
cytofluorographic analysis based on large forward scatter and negative staining by a panel of PE-conjugated cell-specific mAbs to B and T lym-
phocytes, monocytes/macrophages, and NKcells (20): (a) immediately after enrichment; and (b) after resuspension of dendritic cells from den-
dritic cell-T cell clusters that had formed 40 h after initiation of the allogeneic MLR. This excluded nondendritic cell leukocytes from analysis
when dendritic cells were assessed for positive counterstaining by a FITC-conjugated mAbto the accessory ligand of interest: (d, e, f) .....
freshly enriched dendritic cells; clustered dendritic cells; . isotype-matched controls. B lymphoblastoid cell lines that constitutively
express B7/BB I served as positive controls: (c) anti-B7/BBl; . isotype-matched control. T lymphoblast expression of these ligands
was also analyzed using highly purified, APC-free CD34/CD4' T cells stimulated by Con A/PMA: (g, h, i) . unstimulated T cells;
Con A/PMA-stimulated blasts; . isotype-matched controls. T cell activation was confirmed by the expression of p55IL-2R/CD25: (g) un-
stimulated CD3+/CD4+ = 2%CD25+, 96%CD25-; Con A/PMA-stimulated CD3+/CD4+ blasts = 82%CD25+, 16%CD25-. Cytofluorographs
are representative of six experiments. Dendritic cells used here were obtained from the Er-FcR-, plastic nonadherent, metrizamide interface
fraction. Increased purity of the DCpopulation to 80-90%, achieved by panning depletion of residual CD45RA+(4G10) and CD14+ (3C 10) cells
in the metrizamide interface, did not alter the results shown.
nary experiments showed CD4+/CD45RA- and CD4+/
CD45RO-subsets were indistinguishable in their inhibition by
the various mAbstested. Wealso compared T cells obtained by
E-rosetting with those obtained by nonadherence to tissue cul-
ture plastic after 1 h incubation of PBMC, eluted from nylon
wool columns in either case. There were no differences be-
tween T cells prepared by these two methods in terms of mean
peak fluorescence of CD2 (TS2/18) surface expression at 40-
48 h, or alloantigen responses in the MLR(six experiments;
data not shown).
Single mAbs against T cell accessory molecules only par-
tially inhibited the dendritic cell-stimulated allogeneic MLRs,
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Figure 2. The costimulatory role of the B7/BBJ:CD28 accessory li-
gand:receptor couple in the dendritic cell-stimulated allogeneic CD4+
MLR. 1.5 x IO' CD4+T cells were coated with anti-CD2 (TS2/18),
-CD8 (OKT8), -CD28 (9.3), and/or -CD45 (4B2); and 6 x 103 al-
logeneic dendritic cells were coated with anti-BB 1, anti-HLA DR/
DQ, or murine IgMK (TEPC 183). Opsonization was performed di-
rectly in flat-bottomed microwells for 30-60 min at 4°C with gentle
shaking, after which the opposite party of allogeneic T cells or den-
dritic cells was added for a final responder:stimulator ratio of 25:1/
microwell. The final concentrations of mAbs were 1/4, 1/8, and 1/16
dilutions of the following working concentrations: anti-CD2 50 jg/
ml, anti-CD8 50 ,g/ml, anti-CD28 128 ,ug/ml, anti-CD45 90 jg/ml,
anti-BBl 50 jig/ml, anti-HLA DR/DQ72 gg/ml, murine IgMK 50
,ug/ml. MLRswere cultured in triplicate for each mAbdose and con-
dition. Cells were pulsed for 8 h on d4 5 of the MLRwith 1
,uCi3HTdR/microwell. Results shown are the mean counts per min-
ute±standard deviation of triplicates and are representative of six
experiments. Control MLRwithout mAb: 243,376+16,985; anti-
HLADR/DQinhibited proliferation > 99% at all doses.
compared with isotype-matched controls. Anti-CD4 effected
inhibition similar to the others, but is not illustrated. None of
these mAbs blocked the initial binding of allogeneic dendritic
cells and T cells by inverse phase microscopy inspection of the
cultures (not shown). Combinations of these mAbswere addi-
tive in their inhibition of T cell proliferation. Saturating con-
centrations of paired mAbsblocked > 80%, with no substantial
differences between groupings. Total inhibition of T cell prolif-
eration (i.e., 2 97-98%) required saturating doses of at least
three mAbs. Alternatively, by maintaining constant the total
combined dose of two or more mAbs, there was a trend toward
more complete inhibition as the amount of stimulatory alloan-
tigen was decreased by adding fewer allogeneic dendritic cells.
Addition of anti-CD4 did not further enhance the already max-
imal inhibition achieved by the combination of anti-CD2 +
11 a + 28 (data not shown). Two other T cell-reactive mAbs
against molecules involved in T cell signaling and activation,
CD5and CD45 (37), were not inhibitory; resultant T cell prolif-
eration varied less than ± 10% from control MLRcultures
without mAb. Weconclude that dendritic cells deliver several
accessory signals that work in concert in an additive fashion.
B7/BB 1 can now be added to the other known dendritic cell
costimulatory ligands, which together fully activate primary T
cells.
MAbs that inhibit proliferation similarly affect IL-2 release
and blast transformation in the allogeneic MLR. The amount
of 3HTdR incorporation on d4-5 is a distal measurement of
accessory cell-T cell interactions that have occurred much ear-
lier in the dendritic cell-stimulated MLR. Wetherefore evalu-
ated whether two other parameters of T cell activation, IL-2
secretion and blast transformation, were concordant with the
results obtained from 3HTdR incorporation in parallel MLRs
cultured under identical conditions. As shown in Fig. 3, these
two independently measured parameters, IL-2 release by 48 h
of culture and percent blast transformation on d4-5, were both
highly correlated with actual T cell proliferation. Weconclude
that anti-T cell mAbs with specificity for accessory molecule
receptors not only inhibit proliferation in the dendritic cell-
stimulated allogeneic MLRs, but similarly decrease IL-2 re-
lease and actual blast transformation.
Dendritic cells deliver important costimulatory signals early
in the primary allogeneic MLR. As dendritic cells are the most
potent leukocyte for the initiation of T cell responses to alloan-
tigen and mitogen (27), we hypothesized that their costimula-
tory signals were important for their accessory cell function
early in the MLR. As illustrated in Fig. 4, addition of mAbs
against T cell accessory receptor molecules from the outset of
the MLRculture was needed to achieve significant inhibition.
Equivalent inhibition was achieved at any dose of dendritic cell
stimulators used (T:DC 30:1 illustrated; 10:1 and 100:1, not
shown). Addition of mAbs at 24 or 48 h was less effective.
Discussion
Primary antigen-specific T cell responses require peptide anti-
gen presented in association with surface MHCproducts on
APCs (1). Antigen-presentation alone is insufficient, however,
to initiate effective T cell immunity (1, 32). The complete acti-
vation of T lymphocytes in a primary response therefore de-
pends on the concerted delivery by APCs of several accessory
or costimulatory signals in addition to Ag/MHC (1-3).
Wepresent evidence here that human dendritic cells freshly
isolated from peripheral blood express B7/BB 1, the physiologic
ligand for the CD28 T cell accessory molecule. Dendritic cells
in blood (20) and skin (21, 22) also express high amounts of
other accessory ligands, e.g., ICAM-l (CD54), LFA-3 (CD58),
and class II MHCproducts, particularly compared with other
circulating leukocytes. B7/BBI and ICAM-1 (CD54) expres-
sion by dendritic cells is dynamic, increasing after antigen-spe-
cific binding with histoincompatible T cells in the MLR. Other
known accessory molecules, e.g., CD45, LFA-3 (CD58), and
class II MHC, are fairly constant in their expression by blood
dendritic cells.
B7/BB1 is constitutively expressed by B lymphoblastoid
cell lines (B-LCL) (26, 36, 38, 39), as well as by -y-interferon
(IFN)-stimulated macrophages (40). B7/BB1 is the accessory
ligand for CD28 (7, 10) and/or CTLA-4 (11). Several experi-
mental models have documented its costimulatory properties
for T lymphocyte proliferation and lymphokine secretion, by












Table I. Mean Percent Inhibition of Dendritic Cell-stimulated Allogeneic MLRs, by Monoclonal Antibodies
Against T Cell Costimulatory Molecules
A. Variable mAbdose [ug/mlJ per mAbor combination as indicated; Constant CD4' T cell responder: allogeneic dendritic cell stimulator ratio of 30:1
Monoclonal antibodies mAbdose (ug/ml) 15 5 1.5 0.5
aCD2, TS2/18, IgGi 48 46 33 23
aCD1 [a, TS 1 /22, IgG 1 57 44 27 5
aCD28, 9.3, IgG2a* 48 49 52 53
aCD2 + aCDl la Dose indicated 89 80 66 45
aCD2 + aCD28 per each mAb 85 82 78 61
aCDl la +aCD28 85 78 68 54
aCD2 + aCDl la +aCD28* 97 94 85 74
caCD2 + aCDl la Dose indicated is 80 62 37 11
aCD2 + ctCD28 combined Total 80 75 67 56
aCDl la + aCD28 79 70 60 57
aCD2 + aCDl la + ctCD28t 96 84 73 63
B. Constant mAbdose [15 jIg/ml] per mAbor combination as indicated; variable CD4' T cell responder: allogeneic dendritic cell stimulator ratios
Monoclonal antibodies T:DC ratio 30:1 100:1 300:1
aCD2, TS2/18, IgGl 52 56 72
aCD1 a, TS1/22, IgG 1 66 68 77
aCD28, 9.3, IgG2a* 49 74 68
aCD2 + aCDl la 15 ytg/ml per 94 96 97
aCD2 + aCD28 each mAb 86 86 85
aCDl la +aCD28 90 94 92
aCD2 + aCDl la + aCD28t 98 100 98
aCD2 + aCDl la 15 tg/ml total, 82 90 96
aCD2 + aCD28 all mAbscombined 80 80 82
aCDl [a + aCD28 83 92 98
aCD2 + aCDI la + aCD28V 98 99 99
Table I. 1.5 x I05 CD4+T cells were coated directly in triplicate flat-bottomed microwells with the indicated mAbs for 30 min at 4°C, after which
,y-irradiated allogeneic dendritic cells were added. Either the ratio of T cell responders to allogeneic dendritic cell stimulators [T:DC ratio] or
the dose of mAb(s) was held constant, while the other parameter was varied. 3HTdR incorporation was measured over 8-12 h on days 4-5 of
the allogeneic MLR. Percent inhibition was calculated by comparing proliferation in the experimental wells with that in replicate control wells
where T cells had been coated with isotype-matched controls, singly and in combination. Mean percent inhibition was calculated from four
separate allogeneic combinations in A and from two separate allogeneic combinations in B. At a T:DC ratio of 30: 1, the 3HTdR incorporation
[counts per minute ± standard deviation] of quadruplicate control MLRswithout mAbranged from 62,709±15,373 to 216,028±29,669
amongst the different allogeneic pairings. * Addition of aBBl never increased the inhibition effected by aCD28 alone (see also Fig. 2). $ Ad-
dition of ctCD4 to this combination did not increase the already maximal inhibition (see also Fig. 2).
employing B-LCL (36), anti-CD3 mAbtogether with immobi-
lized B7Ig fusion protein (8), or B7-transfected CHOcells (9) as
stimuli for T cell activation. CD28 is a 44-kD homodimer ex-
pressed by CD4' and cytolytic CD8' T cells (41) that appears
to activate human T cells by a direct effect on IL-2 production
(16-19). Stimulation via CD28 induces a nuclear protein that
binds to a specific site in the transcription enhancer region of
the IL-2 gene (19). T cell stimulation via CD28 also prolongs
the longevity of IL-2 mRNA(I17, 18).
Another accessory ligand, ICAM- 1 (CD54), is one of three
molecules that binds the LFA- 1 (CD 1 la:CD1 8) complex on T
cells (6, 42). A second LFA- 1 ligand, ICAM-2, does not yet
have an established role in APC function (6), and the third
ligand has not been characterized (42). Antigen-presentation is
significantly more efficient by virtue of a functional ICAM-
1 :LFA- 1 (CD54:CD 11 a) interaction (43, 44), and stimulation
via either CD2or CD3 increases LFA- 1 (CD I I a) binding avid-
ity for ICAM- 1 (CD54) (45, 46). ICAM- 1 (CD54) and the f2
leukocyte integrins are widely distributed and are present on
dendritic cells (CD54, CDl la/18, CDl lc/18 [20]), T lympho-
cytes (CDl la/18 [6]), and T lymphoblasts (CD54 [6]; see also
Results). CD4is a co-recognition element for class II MHC( 14,
47), engaging a specific MHC-peptide component together
with the CD3/TCRcomplex. CD4is coupled to a lymphocyte-
specific tyrosine kinase (p56lck) that phosphorylates CD3 (48,
49) and may signal T lymphocytes in this manner. Lastly, CD2
is a pan-T cell surface antigen that binds the broadly distrib-
uted LFA-3 (CD58) ligand and is involved in both T cell adhe-
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sion and activation (4, 5). CD2signals T cell activation in con-
junction with the CD3/TCR complex (50), via its cytoplasmic
domain (5).
As different candidate, APCs (e.g., dendritic cells, mono-
cytes, and B cells) are not equally capable of initiating primary
T cell responses (20, 27), we speculate that their accessory li-
gand expression influences function in this respect. Dendritic
cells express higher levels of B7/BB 1, ICAM-I (CD54), LFA-3
(CD58), and class I and II MHCproducts than other circulat-
ing leukocytes, suggesting an already activated phenotype in
peripheral blood. Wecannot exclude some degree of in vitro
activation necessitated by the manipulations and culture in-
volved in the purification of dendritic cells. However, previous
experiments have demonstrated that a dendritic cell-contain-
ing fraction does not increase in stimulatory capacity during 1
or 2 d culture (27). Wehave also compared the different leuko-
cyte subsets obtained during purification of dendritic cells,
each handled identically, for their expression of B7/BB 1. None
of these populations (bulk PBMC,bulk Er', bulk Er-, adherent
Er MOdepleted of dendritic cells, or small B cells) expressed
levels of B7/BB 1 comparable to those of dendritic cells or con-
trol B-LCL. Only a trace subpopulation of adherent Er- MO
expressed B7/BB 1 very slightly above the isotype-matched
control (data not shown). Unlike tonsillar B cells that express


















Figure 3. Accessory ligand:receptor couple involvement in CD4' lym-
phoblast transformation and IL-2 secretion after stimulation by allo-
geneic dendritic cells. Three sets of allogeneic MLRs(CD4+:DC 25: 1)
were cultured in triplicate flat-bottomed microwells in the presence
of mAbs to accessory ligands or receptors, singly and in combination,
versus isotype-matched controls or no mAb. Supernatants were col-
lected from one MLRset at 48 h and assayed for IL-2, based on their
ability to support growth of a CTLL2 line (33). Results are expressed
in terms of IU rhIL-2/ml (1 Cetus Unit = 6 IU rhIL-2). The remain-
ing two sets of MLRswere left in culture. One set was pulsed with
I uCi3HTdR/microwell for 8 h on d4 -- 5 to assess proliferation. The
other set was simultaneously stained with 0.5% vol/vol propidium
iodide and monitored cytofluorographically for viable blast transfor-
mation, based on increased forward scatter (compared with unstimu-
lated CD4' T cell controls) and negative FL2 fluorescence (nonviable
cells are propidium iodide positive in the FL2 channel). The amount
of 3HTdR incorporation was compared with the amount of IL-2 se-
cretion (r = 0.925) or percent blast transformation (r = 0.975) for
each MLRcondition tested (e.g., presence or absence of mAbs at
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Figure 4. Effectiveness of anti-accessory receptor mAbs added at three
sequential time points from the initiation of the dendritic cell-stimu-
lated allogeneic CD4' MLR. Three sets of allogeneic MLRs
(CD4+:DC 30:1) were cultured in triplicate flat-bottomed microwells
in the presence or absence of the indicated mAbs or isotype-
matched/T cell-reactive controls (each at 10 ,g/ml final). MAbswere
added to one set of MLRcultures at time 0 by precoating 1.5 X IO'
CD4' T cells directly in the microwells at 4VC for 30-60 min before
adding allogeneic dendritic cells. Allogeneic CD4' T cells and den-
dritic cells were combined in the other two sets of MLRs, initially
without any mAb. At either 24 or 48 h after initiation of the MLR,
the same mAbsused at time 0 were added to one or the other of the
two remaining sets of MLRcultures. Each plate was placed at 4VC
for 60 min before returning to culture at 370C. All three sets of MLRs
were pulsed with 1 kCi3HTdR/microwell for 12 h d4 -. 5. Results
are expressed in terms of percent inhibition of 3HTdR incorporation
by each mAb, compared with respective isotype-matched controls,
according to the time of mAbaddition to the MLR. Representative
of two experiments.
(36), the exact mechanism by which dendritic cells increase
their expression of B7/BB 1 and ICAM- 1 (CD54) after binding
antigen-specific T cells has not been defined. This phenotypic
upregulation is specific for at least these two molecules, as
LFA-3 (CD58), class II MHC, and CD45 expression remain
relatively constant. Thus, while blood dendritic cells constituti-
vely express an activated phenotype with regard to certain ac-
cessory ligands, they may upregulate other costimulatory mole-
cules as a consequence of antigen-specific engagement between
the CD3/TCR complex and peptide/MHC products. Our data
do not permit specification of the order in which this occurs,
nor does it exclude a role for any other accessory ligand:recep-
tor pair involved in primary T cell activation.
To assess the biologic functions of these accessory ligands,
we added mAbs with specificity for their receptors on the re-
sponding T cells. The absence of detectable FcR on blood den-
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dritic cells permitted the use of intact immunoglobulin for this
purpose, without risking mAb activation of the T cells (27).
Blocking single accessory ligand:receptor couples only partially
inhibited T cell responses in a primary allogeneic MLR. Com-
plete inhibition required interference with at least three acces-
sory ligand:receptor interactions. Alternatively, we observed a
trend toward more complete inhibition by pairwise combina-
tions of mAbs when the amount of antigen was reduced (i.e.,
fewer stimulatory allogeneic dendritic cells in the MLR). T cell
proliferation, as well as IL-2 secretion and blast transforma-
tion, were all affected. Accessory signals seemed to be required
in the first 24 h of a primary T cell response to alloantigen,
since mAbs were substantially less inhibitory once prolifera-
tion had commenced. This was true whether we added anti-ac-
cessory receptor mAbs to MLRcultures at 24 or 48 h, com-
pared with time 0, or whether these mAbswere added to anti-
gen-specific T cell/dendritic cell clusters that had been
separated from nonclustered T cells after 40 h initial culture
(latter not shown). Anti-accessory molecule mAbs were less
effective when added after the initiation of the MLR, either
because costimulatory signals had already been delivered to the
T cells, increased accessory ligand expression escaped inhibi-
tion, steric accessibility into the dendritic cell T lymphocyte
clusters was limited, or the number of stimulatory dendritic
cells was so high in the clusters as to restrict the inhibition that
could be achieved. T cell-reactive, isotype-matched control
mAbs against two other molecules involved in T cell signaling
and activation, CD5 and CD45 (37), were never inhibitory
under any condition. A similar analysis has been conducted of
human tonsillar dendritic cells in T cell oxidative mitogenesis
(51), and most of these same accessory couples contributed to
function (except B7/BB 1:CD28 which was unknown at that
time). Those involved in cell-cell adhesion also blocked clus-
tering, which we did not observe in the human dendritic cell-
stimulated allogeneic MLRand which has also not been docu-
mented in the murine MLR(52).
CD3/TCR occupancy by antigen/MHC is insufficient to
initiate primary T cell responses, as several additional costimu-
latory signals must be delivered by active APCs (1-3). This is
underscored by our finding that complete inhibition of IL-2
secretion, blast transformation, and proliferation by primary T
cells responding to alloantigen requires mAbblock at several
key points. These molecular couples are probably most integral
to APC:T cell interactions when T cells are in a quiescent or
unprimed state or when the amount of presented antigen is
low, resulting in more stringent APCrequirements (27, 32, 35,
53, 54). The use of mitogens or chronically stimulated T cell
lines as responder populations may obscure relevant physio-
logic signals. B7/BB1, ICAM-1 (CD54), and LFA-3 (CD58)
probably work in conjunction with antigen/MHC on dendritic
cells, each delivering a distinct costimulatory signal to the T
lymphocyte (3). B7/BB 1 and ICAM- 1 (CD54), although pres-
ent on circulating dendritic cells, are upregulated after binding
to T cells, presumably increasing T cell transcription and re-
lease of IL-2 via CD28 (8, 9, 16-19), as well as binding avidity
via CDl la (45, 46). Adhesion should be bidirectional, as
ICAM- 1 (CD54) also appears on T lymphoblasts and can inter-
act with LFA- 1 (CDl la:CD1 8) on dendritic cells. B lympho-
blastoid transformation (7, 26, 36, 38, 39) or monocyte expo-
sure to y-IFN (40) upregulates each cell's expression of many of
these same accessory ligands. This should foster productive in-
teraction with T cells already sensitized by dendritic cells,
maintaining and amplifying an effective immune response.
Different APCs therefore do not differ qualitatively in their
capacity to express these accessory ligands, but in their quanti-
tative expression and the factors regulating same. Weconclude
that dendritic cells are unusual among circulating leukocytes in
their comparably higher expression of accessory ligands, and
that these are pertinent to the efficiency with which dendritic
cells in small numbers elicit strong primary T cell proliferative
and effector responses.
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